Northern Trust Corp Has $1.16 Million Stake in Eton Pharmaceuticals, Inc. (NASDAQ:ETON)

Northern Trust Corp lifted its stake in Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) by 35.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 86,957 shares of the company's stock after buying an additional 22,827 shares during the period. Northern Trust Corp owned about 0.33% of Eton Pharmaceuticals worth $1,158,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in the stock. Cannell Capital LLC bought a new stake in shares of Eton Pharmaceuticals in the fourth quarter valued at about $5,079,000. Aristides Capital LLC lifted its stake in shares of Eton Pharmaceuticals by 20.8% in the fourth quarter. Aristides Capital LLC now owns 241,587 shares of the company's stock valued at $3,218,000 after buying an additional 41,587 shares during the period. Connor Clark & Lunn Investment Management Ltd. lifted its stake in shares of Eton Pharmaceuticals by 230.5% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 214,878 shares of the company's stock valued at $2,862,000 after buying an additional 149,864 shares during the period. Renaissance Technologies LLC lifted its stake in shares of Eton Pharmaceuticals by 131.5% in the fourth quarter. Renaissance Technologies LLC now owns 193,100 shares of the company's stock valued at $2,572,000 after buying an additional 109,700 shares during the period. Finally, Thompson Siegel & Walmsley LLC lifted its stake in shares of Eton Pharmaceuticals by 11.3% in the fourth quarter. Thompson Siegel & Walmsley LLC now owns 128,039 shares of the company's stock valued at $1,705,000 after buying an additional 13,009 shares during the period. Institutional investors own 27.86% of the company's stock.

Analysts Set New Price Targets

Several research firms recently issued reports on ETON. HC Wainwright reissued a "buy" rating and issued a $35.00 price target (up previously from $33.00) on shares of Eton Pharmaceuticals in a research report on Thursday. Craig Hallum increased their price target on shares of Eton Pharmaceuticals from $26.00 to $28.00 and gave the stock a "buy" rating in a research report on Wednesday, May 14th. Finally, B. Riley reissued a "buy" rating and issued a $26.00 price target (up previously from $24.00) on shares of Eton Pharmaceuticals in a research report on Friday, May 16th.

Eton Pharmaceuticals Trading Down 0.3%

NASDAQ:ETON traded down $0.05 during mid-day trading on Monday, hitting $18.84. The company's stock had a trading volume of 377,661 shares, compared to its average volume of 205,517. Eton Pharmaceuticals, Inc. has a fifty-two week low of $3.18 and a fifty-two week high of $21.48. The company has a market capitalization of $505.25 million, a price-to-earnings ratio of -85.64 and a beta of 1.22. The stock has a fifty day moving average of $15.92 and a 200-day moving average of $14.76.

Eton Pharmaceuticals (NASDAQ:ETON - Get Free Report) last posted its quarterly earnings results on Tuesday, May 13th. The company reported $0.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by ($0.02). Eton Pharmaceuticals had a negative return on equity of 36.29% and a negative net margin of 15.81%. The business had revenue of $17.28 million during the quarter, compared to analyst estimates of $14.33 million. On average, equities analysts anticipate that Eton Pharmaceuticals, Inc. will post -0.14 earnings per share for the current fiscal year.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.